-
In this issue: Stop smoking drug Chantix rates stronger warning from FDA; Type 2 diabetes surgery on the way?; Vytorin study inconclusive; Influenza A virus found resistant to Tamiflu; FDA actions.
-
-
The Timing Hypothesis argues that estrogen can reduce the risk of coronary heart disease when administered to relatively young postmenopausal women before atherosclerosis has developed to the stage of unstable plaques (plaques with necrosis and inflammation).
-
Heat shock proteins have been of clinical interest in therapeutic vaccination based on their ability to induce significant T- and B-cell responses against microbial pathogens and tumor antigens.
-
Diagnostic ultrasonography is one of the most frequently utilized adjuvant tools clinicians rely upon to make treatment recommendations for suspect adnexal pathology.
-
Among various agents that have been used to prevent preeclampsia, the ones that have attracted the greatest attention have been low-dose aspirin, calcium, and vitamins C and E.
-
Harada and colleagues from Japan conducted a double-blind, placebo-controlled, randomized multicenter trial of a low-dose oral contraceptive for the treatment of dysmenorrhea associated with endometriosis.
-
Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Patent Foramen Ovale (PFO) has been associated with cryptogenic stroke in young individuals, but the association is less clear in older individuals where other causes of stroke predominate.
-
The appropriate treatment of infective endocarditis (IE), to avoid embolic stroke, is unclear. Thus, Dickerman and colleagues explored the International Collaboration on Endocarditis Prospective Cohort Study (ICE-CPS) database to define the temporal occurrence of stroke in relation to antibiotic therapy.